FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
FATE THERAPEUTICS INC revenue by segment
By business segment
By product or service
| Revenue | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|
| Commercial Option Exercise Member | $10.00M | $13.00M | 15.7% | -23.1% |
| Associated with collaboration services | – | $1.30M | – | – |
By region
From the segment and revenue-disaggregation notes of Fate Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.